PUMA BIOTECHNOLOGY, INC. 8-K

What Happened
On May 7, 2026, Puma Biotechnology, Inc. (PBYI) filed a Form 8-K (Item 2.02) to announce and furnish a press release reporting its financial results for the quarter ended March 31, 2026. The press release is attached to the 8-K as Exhibit 99.1 and is incorporated by reference.

Key Details

• Filing date: May 7, 2026.
• Period covered: quarter ended March 31, 2026.
• The press release announcing the quarterly results is furnished as Exhibit 99.1 to the 8-K.
• The filing includes the Cover Page Interactive Data File (Inline XBRL) as Exhibit 104.

Why It Matters
This 8-K signals Puma has publicly released its quarterly earnings and related financial information; those results (revenue, net income/loss, EPS, cash position and any guidance) will be in the attached press release and are material for investors and analysts tracking PBYI. Shareholders should review Exhibit 99.1 and the company’s other SEC filings for the full earnings details and any management commentary that may affect near-term expectations.